BioWorld MedTech

April 29, 2011

Deals roundup: Toshiba Medical plans to buy Vital Images for about $273M

Toshiba Medical Systems (Tokyo) reported that it would buy Vital Images (Minneapolis) for $18.75 a share, or roughly $273 million in the aggregate, through a cash tender offer followed by a merger. (Medical Device Daily) Read More

HexaPOD offers greater accuracy in cancer treatment

International report: Varian Medical reports Chinese approval of its TrueBeam system

Washington roundup: FDAer hints agency concerned about fail-safe wireless health

Financings roundup: Cianna Medical closes $12M in Series B round of funding

MDD's food for med-tech thought

Agreements/contracts: Proven Process to design components of Titan's Amadeus

HIT roundup: OraMetrix selects Camstar platform for future growth

Restructuring roundup: Medtronic laying off 268 in Twin Cities

Patent watch: AquaStar snags patent for enzyme testing platform

People in the News

Med-Tech Notes

Court Report: Palomar files patent lawsuit against Candela

Product Briefs

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...